Moleculin Announces Positive Independent Report of No Cardiotoxicity in Annamycin Phase 1 To Date

About this update from Moleculin Biotech, Inc.

[{"type":"text","content":"Supports Moleculin's Claim that Annamycin is a \"Next Generation\" Anthracycline\n\n\nHOUSTON, Feb. 20, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (\"Moleculin\" or the \"Company\"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that it has received an independent assessment of the absence of cardiotoxicity in patients treated with Annamycin in both its US and European open label and single arm Phase 1 clinical trials. Data from the first 5 patients in the US and the first 9 patients in Europe were made available to an expert in chemotherapy who is affiliated with a leading cancer research institute in assessing cardiotoxicity. After review of this data, the independent expert concluded that he \"does not see evidence of cardio-toxicity.\"\n\n \n \n\n \nThe data made available included left ventricular ejection fraction (LVEF) as determined by echocardiograms, ECHO strain imaging, and Troponin levels. For a small population of patients, ECHO strains were not provided due to the limitations of delivery of such data by the clinical sites. \"ECHO strain imaging\" is a method in echocardiography (medical ultrasound) for measuring regional or global deformation of the myocardium (heart muscle). By strain rate imaging, the simultaneous function of different regions can be displayed and measured. Cardiac health biomarkers such as blood Troponin levels are considered an indicator of potential long-term heart damage.\n\"We are pleased to receive this independent assessment which further validates the absence of cardiotoxicity in patients to date of Annamycin,\" stated Wally Klemp, Chairman and CEO of Moleculin. \"Currently approved anthracyclines are notoriously cardiotoxic, so demonstrating that Annamycin is not cardiotoxic, even in patients who have received more than the lifetime maximum cumulative anthracycline exposure established by the FDA, supports our claim that Annamycin is truly in a class by itself, and indeed a 'Next Generation' anthracycline.\" He continued, \"We are excited to continue to demonstrate Annamycin's excellent safety profile. We believe continuing to demonstrate the lack of cardiotoxicity, along with initial efficacy data shown while increasing the dosage to a therapeutic level, will make Annamycin an extrem...

More updates from Moleculin Biotech, Inc.